Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2025 | Buy → Hold | D. Boral Capital | |
| 10/25/2024 | $25.00 | Hold → Buy | Maxim Group |
| 12/29/2023 | $36.00 | Buy | Canaccord Genuity |
| 7/7/2021 | $45.00 → $150.00 | Buy | Maxim Group |
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced that on March 26, 2025, it received notice (the "Notice") from the New York Stock Exchange (NYSE) that it is no longer in compliance with the NYSE continued listing standards set forth in Section 802.01B of the NYSE's Listed Company Manual due to the fact that the Company's average global market capitalization over a consecutive 30 trading-day period was less than $50 million while its stockholde
MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its participation in the AD/PD™ 2025 taking place April 1-5 in Vienna. "We are at a pivotal moment in our company's journey as we have entered the late clinical stages for both Alzheimer's and Parkinson's. It is incredibly rewarding to see our work bring us here, once again supporting that our drug is efficacious and safe across both indications," commented Maria Maccecchini, Ph.D., Founder and CEO of Annovis. "A
MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and fourth quarter/full year 2024 financial results. In 2024, Annovis made significant progress by advancing the buntanetap program, successfully completing two clinical trials—Phase 2/3 AD and Phase 3 PD. Both studies yielded promising results, reinforcing buntanetap's ability to improve cognition in AD and PD patients, as well as motor function in PD patients. Building on this
Data Shows Statistically Significant Improvements in Speed and Motor Function in PD PatientsAnnovis Bio to Request Meeting with FDA on Next Steps in Clinical DevelopmentInvestor Conference Call to be Hosted Tuesday, October 5th, 2021, at 9:00 am ETBerwyn, Pennsylvania--(Newsfile Corp. - October 5, 2021) - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results from the completed dose response Phase 2 clinical trial of ANVS401 in 54 PD patients, which found that once-daily ANVS401 was superior to placebo in improving motor funct
8-K - Annovis Bio, Inc. (0001477845) (Filer)
10-K - Annovis Bio, Inc. (0001477845) (Filer)
8-K - Annovis Bio, Inc. (0001477845) (Filer)
SC 13G/A - Annovis Bio, Inc. (0001477845) (Subject)
SC 13G - Annovis Bio, Inc. (0001477845) (Subject)
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis' clinical trials. "We are thrilled to welcome Matthew Peterson to our team," said Cheng Fang, Ph.D., Senior Vice President, Research and Development,
BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD) today announced the appointment of Andrew Walsh as VP, Finance. "We remain steadfast in advancing our lead candidate buntanetap, as we gear up to receive pivotal data from both our Alzheimer's and Parkinson's clinical trials in 2024. The addition of Andrew Walsh to our team marks another step in our growth plans," said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. "Andrew brings 12 years of extensive experience in finance operations, adding a
TheracosBio today announced the appointment of former US Congressman Jim Greenwood to the Board of Directors of its parent company and Jeff McGroarty, MBA, as its Chief Financial Officer. Congressman Greenwood is an established leader in life sciences across business and public policy, and Mr. McGroarty has served as a CFO of public and private life sciences and technology companies. Both newly appointed team members will help shape the commercial strategy for Brenzavvy™ (bexagliflozin), a recently FDA-approved treatment for type 2 diabetes. "Accomplished leaders, Jim and Jeff will be valuable members of our team at this critical time for TheracosBio," said Albert R. Collinson, Ph.D., Pres
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
4 - Annovis Bio, Inc. (0001477845) (Issuer)
D. Boral Capital downgraded Annovis Bio from Buy to Hold
Maxim Group upgraded Annovis Bio from Hold to Buy and set a new price target of $25.00
Canaccord Genuity initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $36.00